Version 1
: Received: 10 October 2018 / Approved: 11 October 2018 / Online: 11 October 2018 (02:53:11 CEST)
How to cite:
Seidi, K.; Manjili, M..H.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Preprints2018, 2018100225. https://doi.org/10.20944/preprints201810.0225.v1
Seidi, K.; Manjili, M..H.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Preprints 2018, 2018100225. https://doi.org/10.20944/preprints201810.0225.v1
Seidi, K.; Manjili, M..H.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Preprints2018, 2018100225. https://doi.org/10.20944/preprints201810.0225.v1
APA Style
Seidi, K., Manjili, M..H., Jahanban-Esfahlan, R., & Javaheri, T. (2018). Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. Preprints. https://doi.org/10.20944/preprints201810.0225.v1
Chicago/Turabian Style
Seidi, K., Rana Jahanban-Esfahlan and Tahereh Javaheri. 2018 "Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer" Preprints. https://doi.org/10.20944/preprints201810.0225.v1
Abstract
Tumor dormancy, a clinically undetectable state of cancer, makes a major contribution to the development of multidrug resistance (MDR), minimum residual disease (MRD), tumor outgrowth, cancer relapse, and metastasis. Despite its high incidence, the whole picture of dormancy-regulated molecular programs is far from clear. That is, it is unknown when and which dormant cells will resume proliferation causing late relapse, and which will remain asymptomatic and harmless to their hosts. Thus, identification of dormancy-related culprits and understanding their roles can help predict cancer prognosis and may increase the probability of a timely therapeutic intervention for the desired outcome. Here, we provide a comprehensive review of the dormancy-dictated molecular mechanisms, including an angiogenic switch, immune escape, cancer stem cells, extra cellular matrix (ECM) remodeling, metabolic reprogramming, miRNAs, epigenetic modifications, and stress-induced-p38 signaling pathways. Further, we analyze the possibility of leveraging these dormancy-related molecular cues to outmaneuver cancer, and discuss the implications of such approaches in cancer treatment.
Keywords
tumor dormancy; tumor relapse; tumor escape; metastasis; cancer therapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
